Search


Current filters:

Start a new search
Add filters:

Use filters to refine the search results.


Results 1-10 of 64 (Search time: 0.004 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2009A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph plus CML or relapsed/refractory Ph plus ALLTojo, A.; Usuki, K.; Urabe, A.; Maeda, Y.; Kobayashi, Y.; Jinnai, I.; Ohyashiki, K.; Nishimura, M.; Kawaguchi, T.; Tanaka, H.; Miyamura, K.; Miyazaki, Y.; Hughes, T.; Branford, S.; Okamoto, S.; Ishikawa, J.; Okada, M.; Usui, N.; Tanii, H.; Amagasaki, T.; et al.
2003Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemiaO'Brien, S.; Guilhot, F.; Larson, R.; Gathmann, I.; Baccarani, M.; Cervantes, F.; Cornelissen, J.; Fischer, T.; Hochhaus, A.; Hughes, T.; Lechner, K.; Nielsen, J.; Rousselot, P.; Reiffers, J.; Saglio, G.; Shepherd, J.; Simonsson, B.; Gratwohl, A.; Goldman, J.; Kantarjian, H.; et al.
2004Interferon-α-2b and oral cytarabine ocfosfate for newly diagnosed chronic myeloid leukaemiaMollee, P.; Arthur, C.; Hughes, T.; Januszewicz, H.; Grigg, A.; Bradstock, K.; Wolf, M.; Gibson, J.; Schwarer, A.; Spencer, A.; Browett, P.; Hawkins, T.; Seldon, M.; Herrmann, R.; Watson, A.; Seymour, J.; Martin, N.; Shina, S.; Low, C.; Wright, S.; et al.
2003Successful peripheral blood stem cell mobilisation with filgrastim in patients with chronic myeloid leukaemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time PCRHui, C.; Goh, K.; White, D.; Branford, S.; Grigg, A.; Seymour, J.; Kwan, Y.; Walsh, S.; Hoyt, R.; Trickett, A.; Rudzki, Z.; Ma, D.; To, L.; Hughes, T.
2007BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteriaBranford, S.; Seymour, J.; Grigg, A.; Arthur, C.; Rudzki, Z.; Lynch, K.; Hughes, T.
2003Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phaseBranford, S.; Rudzki, Z.; Harper, A.; Grigg, A.; Taylor, K.; Durrant, S.; Arthur, C.; Browett, P.; Schwarer, A.; Ma, D.; Seymour, J.; Bradstock, K.; Joske, D.; Lynch, K.; Gathmann, I.; Hughes, T.
2006Five-year follow-up of patients receiving imatinib for chronic myeloid leukemiaDruker, B.; Guilhot, F.; O'Brien, S.; Gathmann, I.; Kantarjian, H.; Gattermann, N.; Deininger, M.; Silver, R.; Goldman, J.; Stone, R.; Cervantes, F.; Hochhaus, A.; Powell, B.; Gabrilove, J.; Rousselot, P.; Reiffers, J.; Cornelissen, J.; Hughes, T.; Agis, H.; Fischer, T.; et al.
2005Dynamics of chronic myeloid leukaemiaMichor, F.; Hughes, T.; Iwasa, Y.; Branford, S.; Shah, N.; Sawyers, C.; Nowak, M.
2002Dual transcription of b2a2 and b3a2 BCR-ABL transcripts in chronic myeloid leukaemia is confined to patients with a linked polymorphism within the BCR geneBranford, S.; Hughes, T.; Rudzki, Z.
2000A novel BCR-ABL transcript (e8a2) with the insertion of an inverted sequence of ABL intron 1b in a patient with Philadelphia-positive chronic myeloid leukaemiaBranford, S.; Rudzi, Z.; Hughes, T.